The Kock Pouch pp 143-165 | Cite as

Management of de Novo Crohn’s Disease after Reconstructive Surgery with Continent Ileostomy in Ulcerative Colitis

  • Henrik HjortswangEmail author


Pouchitis, i.e. de novo inflammation of the ileal pouch, is a common complication in patients with ileal pouch anal anastomosis (IPAA) or continent ileostomy (Kock pouch) following colectomy for Ulcerative Colitis. It has an endoscopic appearance resembling the colorectal inflammation of Ulcerative Colitis, and causes symptoms with increased stool frequency, urgency, abdominal cramps, mucous and/or bloody exudates, and fever. The cumulative incidence is increasing with time from ileostomy takedown and is reported to affect more than 50% of patients within 10 years. About 10% develop chronic antibiotic refractory pouchitis. Some patients with pouchitis develop an inflammation with a phenotype resembling Crohn’s disease, although they preoperatively had a clinical presentation, endoscopic features and histopathology data indicating they had Ulcerative Colitis, including reexamination of the pathology specimens. There is no agreed definition of de novo Crohn’s disease of the pouch, but it often includes a Crohn-like ulcerative inflammation, involvement of the pre-pouch afferent limb, and non-anastomotic complications with strictures or fistulas unrelated to surgery. Making a firm diagnosis of de novo Crohn’s disease of the pouch can be challenging since the distinction of de novo Crohn’s disease from chronic antibiotic resistant pouchitis or technical complications related to surgery is often difficult. Making an accurate diagnosis of Crohn of the pouch versus a postoperative complication is important for both decisions regarding medical management, and pouch excision versus reconstruction. Most patients diagnosed with Crohn’s disease will no longer be considered for pouch reconstructive surgery. There is very limited data on the medical management of de novo Crohn of pouches and the study quality is often poor. The management of de novo Crohn of the continent ileostomy is therefore mainly taken from management of IBD in general and Crohn’s disease in particular. A successful management is facilitated by cooperation in a multidisciplinary team with gastroenterologists and colorectal surgeons, closely involving the patient in therapeutic decisions with a person centered approach.


  1. 1.
    Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg. 2000;24:851–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234–9.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Romanos J, Samarasekera DN, Stebbing JF, et al. Outcome of 200 restorative proctocolectomy operations: the John Radcliffe hospital experience. Br J Surg. 1997;84:814–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Svaninger G, Nordgren S, Oresland T, et al. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol. 1993;28:695–700.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Banasiewicz T, Marciniak R, Kaczmarek E, et al. The prognosis of clinical course and the analysis of the frequency of the inflammation and dysplasia in the intestinal J-pouch at the patients after restorative proctocolectomy due to FAP. Int Colorectal Dis. 2011;26:1197–203.CrossRefGoogle Scholar
  7. 7.
    Meagher AP, Farouk R, Dozois RR, et al. J-ileal pouch anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Lovegrove RE, Tilney HS, Heriot AG, et al. A comparison of adverse events and functional outcomes after restorative protocolectomy for familial adenoma-Tous polyposis and ulcerative colitis. Dis Colon Rectum. 2006;49:1293–306.PubMedCrossRefGoogle Scholar
  9. 9.
    Zaghiyan K, Kamiński JP, Barmparas G, Fleshner P. De novo Crohn’s disease after ileal pouch anal anastomosis for ulcerative colitis and inflammatory bowel disease unclassified: long-term follow-up of a prospective inflammatory bowel disease registry. Am Surg. 2016;82:977–81.PubMedGoogle Scholar
  10. 10.
    Shen B. Crohn’s disease of the ileal pouch: reality, diagnosis, and management. Inflamm Bowel Dis. 2009;15:284–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD study group. Eur J Gastroenterol Hepatol. 1997;9:353–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Shen B, Fazio VW, Remzi FH, et al. Risk factors for clinical phenotypes of Crohn’s disease of the pouch. Am J Gastroenterol. 2006;101:2760–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Wolf JM, Achkar J-P, Lashner BA, et al. Afferent limb ulcers predict Crohn’s disease in patients with ileal pouch-anal anastomosis. Gastroenterology. 2004;126:1686–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Shen B, Fazio VW, Remzi FH, et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouchanal anastomoses. Am J Gastroenterol. 2005;100:93–101.PubMedCrossRefGoogle Scholar
  15. 15.
    Deutsch AA, McLeod RS, Cullen J, Cohen Z. Results of the pelvic-pouch procedure in patients with Crohn’s disease. Dis Colon Rectum. 1991;34:475–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Grobler SP, Hosie KB, Keighley MR. Randomized trial of loop ileostomy in restorative proctocolectomy. Br J Surg. 1992;79:903–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Hyman NH, Fazio VW, Tuckson WB, Lavery IC. Consequences of ileal pouch-anal anastomosis for Crohn’s colitis. Dis Colon Rectum. 1991;34:653–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Shen B, Fazio VW, Remzi FH, et al. Clinical features and quality of life in patients with different phenotypes of Crohn’s disease of the ileal pouch. Dis Colon Rectum. 2007;50:1450–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Stein RB, Lichtenstein GR. Complications after ileal pouch-anal anastomosis. Semin Gastrointest Dis. 2000;11:2–9.PubMedGoogle Scholar
  20. 20.
    Shen B, Fazio VW, Remzi FH, Lashner BA. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005;100:2796–807.PubMedCrossRefGoogle Scholar
  21. 21.
    Lightner AL, Fletcher JG, Pemberton JH, et al. Crohn’s disease of the pouch: a true diagnosis or an oversubscribed diagnosis of exclusion? Dis Colon Rectum. 2017;60:1201–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Tekkis PP, Fazio VW, Remzi F, et al. Risk factors associated with ileal pouch-related fistula following restorative proctocolectomy. Br J Surg. 2005;92:1270–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Ferrante M, D’Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn’s disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis. 2010;16:243–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Bell AJ, Price AB, Forbes A, et al. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Color Dis. 2006;8:402–10.CrossRefGoogle Scholar
  25. 25.
    McLaughlin SD, Clark SK, Bell AJ, et al. Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2009;52:879–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Samaan MA, de Jong D, Sahami S, et al. Incidence and severity of prepouch ileitis: a distinct disease entity or a manifestation of refractory pouchitis? Inflamm Bowel Dis. 2016;22:662–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Segal JP, McLaughlin SD, Faiz OD, Clark SK, Hart AL. Incidence and long-term implications of prepouch ileitis: an observational study. Dis Colon Rectum. 2018;23 [Epub ahead of print].Google Scholar
  28. 28.
    Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta-analysis. Radiology. 2005;236:95–101.PubMedCrossRefGoogle Scholar
  29. 29.
    Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn’s disease. Am J Roentgenol. 2001;177:1325–32.CrossRefGoogle Scholar
  30. 30.
    Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology. 2008;247:64–79.CrossRefGoogle Scholar
  31. 31.
    Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–45.PubMedCrossRefGoogle Scholar
  32. 32.
    Qiu Y, Mao R, Chen BL, et al. Systematic review with meta-analysis: magnetic resonance enterography vs. computed tomography enterography for evaluating disease activity in small bowel Crohn’s disease. Aliment Pharmacol Ther. 2014;40:134–46.PubMedCrossRefGoogle Scholar
  33. 33.
    Wold PB, Fletcher JG, Johnson CD, et al. Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology. 2003;229:275–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Takenaka K, Ohtsuka K, Kitazume Y, Matsuoka K, Fujii T, Nagahori M, Kimura M, Fujioka T, Araki A, Watanabe M. Magnetic resonance evaluation for small bowel strictures in Crohn’s disease: comparison with balloon enteroscopy. J Gastroenterol. 2017;52:879–88.PubMedCrossRefGoogle Scholar
  35. 35.
    Rispo A, Imperatore N, Testa A, et al. Bowel damage in Crohn’s disease: direct comparison of ultrasonography-based and magnetic resonance-based Lemann index. Inflamm Bowel Dis. 2017;23:143–51.PubMedCrossRefGoogle Scholar
  36. 36.
    Tillack C, Seiderer J, Brand S, et al. Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn’s disease. Inflamm Bowel Dis. 2008;14:1219–28.PubMedCrossRefGoogle Scholar
  37. 37.
    Geboes K, Colombel JF, Greenstein A, et al. Pathology task force of the International Organization of Inflammatory Bowel Diseases. Indeterminate colitis: a review of the concept--what’s in a name? Inflamm Bowel Dis. 2008;14:850–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Bernades P, Hecketsweiler P, Benozio M, et al. Proposal of a system of criteria for the diagnosis of cryptogenetic inflammatory enterocolitis (Crohn’s disease and hemorrhagic rectocolitis). A cooperative study by the cryptogenic enterocolitis study group. Gastroenterol Clin Biol. 1978;2:1047–54.PubMedGoogle Scholar
  39. 39.
    Li Y, Wu B, Shen B. Diagnosis and differential diagnosis of Crohn’s disease of the ileal pouch. Curr Gastroenterol Rep. 2012;14:406–13.PubMedCrossRefGoogle Scholar
  40. 40.
    Garrett KA, Remzi FH, Kirat HT, et al. Outcome of salvage surgery for ileal pouches referred with a diagnosis of Crohn’s disease. Dis Colon Rectum. 2009;52:1967–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Zundler S, Neurath MF. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S19–28.PubMedGoogle Scholar
  42. 42.
    Sachar DB, Walfish A. Inflammatory bowel disease: one or two diseases? Curr Gastroenterol Rep. 2013;15:298.PubMedCrossRefGoogle Scholar
  43. 43.
    Louis E, Van Kemseke C, Reenaers C. Necessity of phenotypic classification of inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2011;(25 Suppl 1):S2–7.CrossRefGoogle Scholar
  44. 44.
    Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349–55.PubMedCrossRefGoogle Scholar
  45. 45.
    Ellinghaus D, Bethune J, Petersen BS, et al. The genetics of Crohn’s disease and ulcerative colitis—status quo and beyond. Scand J Gastroenterol. 2015;50:13–23.PubMedCrossRefGoogle Scholar
  46. 46.
    Bengtson MB, Solberg C, Aamodt G, et al. Clustering in time of familial IBD separates ulcerative colitis from Crohn’s disease. Inflamm Bowel Dis. 2009;15:1867–74.PubMedCrossRefGoogle Scholar
  47. 47.
    Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRefGoogle Scholar
  48. 48.
    Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152:313–21.PubMedCrossRefGoogle Scholar
  49. 49.
    Bridger S, Lee JC, Bjarnason I, et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn’s disease and non-smokers develop ulcerative colitis. Gut. 2002;51:21–5.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1–10.PubMedCrossRefGoogle Scholar
  51. 51.
    Theochari NA, Stefanopoulos A, Mylonas KS, Economopoulos KP. Antibiotics exposure and risk of inflammatory bowel disease: a systematic review. Scand J Gastroenterol. 2018;53:1–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Aniwan S, Tremaine WJ, Raffals LE, et al. Antibiotic use and new-onset inflammatory bowel disease in Olmsted county, Minnesota: a population-based case-control study. J Crohns Colitis. 2018;12:137–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661–73.PubMedCrossRefGoogle Scholar
  54. 54.
    Orel R, Kamhi TT. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol. 2014;20:11505–24.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Gomollón F, Dignass A, Annese V, et al. ECCO. 3rd European evidence-based consensus on the diagnosis and Management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.PubMedCrossRefGoogle Scholar
  56. 56.
    Lohmuller JL, Pemberton JH, Dozois RR, et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg. 1990;211:622–7. discussion 7–9PubMedPubMedCentralGoogle Scholar
  57. 57.
    Coffey JC, Rowan F, Burke J, et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol. 2009;104:1013–23.PubMedCrossRefGoogle Scholar
  58. 58.
    Wu H, Shen B. Pouchitis and pouch dysfunction. Med Clin North Am. 2010;94:75–92.PubMedCrossRefGoogle Scholar
  59. 59.
    Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J Clin Gastroenterol. 2004;38:S44–50.PubMedCrossRefGoogle Scholar
  60. 60.
    Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13:713–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum. 2007;50:498–508.PubMedCrossRefGoogle Scholar
  62. 62.
    Isaacs KL, Sandler RS, Abreu M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007;13:1250–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002;16:909–17.PubMedCrossRefGoogle Scholar
  65. 65.
    Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;6:CD001176.Google Scholar
  67. 67.
    Gionchetti P, Amadini C, Rizzello F, et al. Probiotics for the treatment of postoperative complications following intestinal surgery. Best Pract Res Clin Gastroenterol. 2003;17:821–31.PubMedCrossRefGoogle Scholar
  68. 68.
    Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005;22:721–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075–82.PubMedCrossRefGoogle Scholar
  71. 71.
    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–14.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Lim M, Adams JD, Wilcox M, et al. An assessment of bacterial dysbiosis in pouchitis using terminal restriction fragment length polymorphisms of 16S ribosomal DNA from pouch effluent microbiota. Dis Colon Rectum. 2009;52:1492–500.PubMedCrossRefGoogle Scholar
  74. 74.
    Sokol H, Lay C, Seksik P, et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis. 2008;14:858–67.PubMedCrossRefGoogle Scholar
  75. 75.
    Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in Pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol. 2007;5:352–60.PubMedCrossRefGoogle Scholar
  76. 76.
    McLaughlin SD, Clark SK, Tekkis PP, et al. The bacterial pathogenesis and treatment of pouchitis. Therap Adv Gastroenterol. 2010;3:335–48.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Quinn KP, Lightner AL, Pendegraft RS, et al. Pouchitis is a common complication in patients with familial adenomatous polyposis following ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2016;14:1296–301.PubMedCrossRefGoogle Scholar
  78. 78.
    Salemans JM, Nagengast FM, Lubbers EJ, Kuijpers JH. Postoperative and long-term results of ileal pouch-anal anastomosis for ulcerative colitis and familial polyposis coli. Dig Dis Sci. 1992;37:1882–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Shepherd NA, Healey CD, Warren BE, et al. Distribution ofmucosal pathology and anassessment ofcolonic phenotypic changein the pelvicheal reservoir. Gut. 1993;34:101–5.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Kmiot WA, Youngs D, Tudor R, et al. Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis. Br J Surg. 1993;80:1445–9.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Duffy M, O’Mahony L, Coffey JC, et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum. 2002;45:384–8.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Bath S, Selinger CP, Leong RWL. The pathogenesis of primary pouchitis following ileal pouch-anal anastomosis: a review of current hypotheses. J Gastroenterol. 2011;1:7–12.Google Scholar
  83. 83.
    Ruseler-Van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut. 1994;35:658–64.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Tannock GW, Lawley B, Munro K, et al. Comprehensive analysis of the bacterial content of stool from patients with chronic pouchitis, normal pouches, or familial adenomatous polyposis pouches. Inflamm Bowel Dis. 2012;18:925–34.PubMedCrossRefGoogle Scholar
  85. 85.
    Bambury N, Coffey JC, Burke J, et al. Sulphomucin expression in ileal pouches: emerging differences between ulcerative colitis and familial adenomatous polyposis pouches. Dis Colon Rectum. 2008;51:561–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Fumery M, Dulai PS, Meirick P, et al. Systematic review with meta-analysis: recurrence of Crohn’s disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2017;45:381–90.PubMedCrossRefGoogle Scholar
  87. 87.
    Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991;338:771–4.PubMedCrossRefGoogle Scholar
  88. 88.
    D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Buisson A, Chevaux JB, Allen PB, et al. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther. 2012;35:625–33.PubMedCrossRefGoogle Scholar
  90. 90.
    Shamah S, Schneider J, Korelitz BI. High incidence of recurrent Crohn’s disease following colectomy for ulcerative colitis revealed with long follow-up. Dig Dis Sci. 2018;63:446–51.PubMedCrossRefGoogle Scholar
  91. 91.
    Du P, Sun C, Ashburn J, et al. Risk factors for Crohn’s disease of the neo-small intestine in ulcerative colitis patients with total proctocolectomy and primary or secondary ileostomies. J Crohns Colitis. 2015;9:170–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Koriche D, Gower-Rousseau C, Chater C, et al. Post-operative recurrence of Crohn’s disease after definitive stoma: an underestimated risk. Int J Color Dis. 2017;32:453–8.CrossRefGoogle Scholar
  93. 93.
    Nessar G, Fazio VW, Tekkis P, et al. Long-term outcome and quality of life after continent ileostomy. Dis Colon Rectum. 2006;49:336–44.CrossRefGoogle Scholar
  94. 94.
    Handelsman JC, Gottlieb LM, Hamilton SR. Crohn’s disease as a contraindication to Kock pouch (continent ileostomy). Dis Colon Rectum. 1993;36:840–3.CrossRefGoogle Scholar
  95. 95.
    Brown CJ, Maclean AR, Cohen Z, et al. Crohn’s disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure. Dis Colon Rectum. 2005;48:1542–9.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Gemlo BT, Wong WD, Rothenberger DA, Goldberg SM. Ileal pouch-anal anastomosis. Patterns of failure. Arch Surg. 1992;127:784–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomosis: complications and function in 1005 patients. Ann Surg. 1995;222:120–7.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Neilly P, Neill ME, Hill GL. Restorative proctocolectomy with ileal pouch-anal anastomosis in 203 patients: the Auckland experience. Aust NZ J Surg. 1999;69:22–7.CrossRefGoogle Scholar
  99. 99.
    Keighley MRB. The final diagnosis in pouch patients for presumed ulcerative colitis may change to Crohn’s disease: patients should be warned of the consequences. Acta Chir Ingoslav. 2000;47(suppl 4):27–31.Google Scholar
  100. 100.
    Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum. 2000;43:1487–96.PubMedCrossRefGoogle Scholar
  101. 101.
    Peyrègne V, Francois Y, Gilly FN, Descos JL, Flourie B, Vignal J. Outcome of ileal pouch after secondary diagnosis of Crohn’s disease. Int J Color Dis. 2000;15:49–53.CrossRefGoogle Scholar
  102. 102.
    Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg. 2003;238:229–34.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Hartley JE, Fazio VW, Remzi FH, et al. Analysis of the outcome of ileal pouch-anal anastomosis in patients with Crohn’s disease. Dis Colon Rectum. 2004;47:1808–15.PubMedCrossRefGoogle Scholar
  104. 104.
    Murrell ZA, Melmed GY, Ippoliti A, et al. A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum. 2009;52:872–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Delaney CP, Remzi FH, Gramlich T, et al. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Ann Surg. 2002;236:43–8.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Melmed GY, Fleshner PR, Bardakcioglu O, et al. Family history and serology predict Crohn’s disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008;51:100–8.PubMedCrossRefGoogle Scholar
  107. 107.
    Shen B, Remzi FH, Hammel JP, et al. Family history of Crohn’s disease increases the risk for Crohn’s disease of ileal pouch-anal anastomosis. Inflamm Bowel Dis. 2009;15:163–70.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Stahlberg D, Gullberg K, Liljeqvist L, et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum. 1996;39:1012–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol. 2003;38:1055–8.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Wasmuth HH, Svinsås M, Tranø G, et al. Surgical load and long-term outcome for patients with Kock continent ileostomy. Color Dis. 2007;9:713–7.CrossRefGoogle Scholar
  111. 111.
    Köhler LW, Pemberton JH, Zinsmeister AR, Kelly KA. Quality of life after proctocolectomy. A comparison of Brooke ileostomy, Kock pouch, and ileal pouch-anal anastomosis. Gastroenterology. 1991;101:679–84.PubMedCrossRefGoogle Scholar
  112. 112.
    Crawshaw A, Williams J, Woodhouse F. The Kock pouch reconsidered: an alternative surgical technique. Br J Nurs. 2014;23:S26–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Taleban S, Van Oijen MG, Vasiliauskas EA, et al. Colectomy with permanent end ileostomy is more cost-effective than ileal pouch-anal anastomosis for Crohn’s colitis. Dig Dis Sci. 2016;61:550–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Dehni N, Remacle G, Dozois RR, et al. Salvage reoperation for complications after ileal pouch-anal anastomosis. Br J Surg. 2005;92:748–53.PubMedCrossRefGoogle Scholar
  115. 115.
    Baixauli J, Delaney CP, Wu JS, et al. Functional outcome and quality of life after repeat ileal pouchanal anastomosis for complications of ileoanal surgery. Dis Colon Rectum. 2004;47:2–11.PubMedCrossRefGoogle Scholar
  116. 116.
    Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152:351–61.PubMedCrossRefGoogle Scholar
  118. 118.
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.PubMedCrossRefGoogle Scholar
  119. 119.
    D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–7.PubMedCrossRefGoogle Scholar
  120. 120.
    Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn’s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41:734–46.PubMedCrossRefGoogle Scholar
  121. 121.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.PubMedCrossRefGoogle Scholar
  122. 122.
    Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5–36.CrossRefGoogle Scholar
  123. 123.
    Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Shen B, Remzi FH, Lavery IC, et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2008;6:145–58.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Orscheln ES, Dillman JR, Towbin AJ, et al. Penetrating Crohn disease: does it occur in the absence of stricturing disease? Abdom Radiol (NY). 2017.; [Epub ahead of print]Google Scholar
  126. 126.
    Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Color Dis. 2005;7:182.CrossRefGoogle Scholar
  127. 127.
    Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol. 2008;8:26.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Kelly OB, Rosenberg M, Tyler AD, et al. Infliximab to treat refractory inflammation after pelvic pouch surgery for ulcerative colitis. J Crohns Colitis. 2016;10:410–7.PubMedCrossRefGoogle Scholar
  129. 129.
    Huguet M, Pereira B, Goutte M, et al. Systematic review with meta-analysis: anti-TNF therapy in refractory pouchitis and Crohn’s disease-like complications of the pouch ffter ileal pouch-anal anastomosis following colectomy for ulcerative colitis. Inflamm Bowel Dis. 2018;24:261–8.PubMedCrossRefGoogle Scholar
  130. 130.
    Bär F, Kühbacher T, Dietrich NA, et al. German IBD study group. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Aliment Pharmacol Ther. 2018;47:581–7.PubMedCrossRefGoogle Scholar
  131. 131.
    Verstockt B, Claeys C, Van Assche G, et al.. Vedolizumab can induce clinical remission in patients with chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. The ECCO congress, Vienna 2018, abstract P624.CrossRefGoogle Scholar
  132. 132.
    Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;6:CD000296.Google Scholar
  133. 133.
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. Canadian inflammatory bowel disease study group. N Engl J Med. 1994;331:836–41.PubMedCrossRefGoogle Scholar
  134. 134.
    Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–5.PubMedCrossRefGoogle Scholar
  135. 135.
    Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The global budesonide study group. Gut. 1997;41:209–14.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli budesonide study group. Gastroenterology. 1998;115:835–40.PubMedCrossRefGoogle Scholar
  137. 137.
    Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008:CD006792.Google Scholar
  138. 138.
    Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3:113–21.PubMedCrossRefGoogle Scholar
  139. 139.
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.PubMedCrossRefGoogle Scholar
  141. 141.
    Kuenzig ME, Rezaie A, Seow CH, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD002913.298.Google Scholar
  142. 142.
    Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003:CD000301.Google Scholar
  143. 143.
    Summers RW, Switz DM, Sessions JT, et al. National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology. 1979;77:847–69.PubMedGoogle Scholar
  144. 144.
    Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–66.PubMedGoogle Scholar
  145. 145.
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–2.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.PubMedCrossRefGoogle Scholar
  147. 147.
    Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–30.PubMedCrossRefGoogle Scholar
  148. 148.
    Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779–89.PubMedCrossRefGoogle Scholar
  149. 149.
    Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41:734–46.PubMedCrossRefGoogle Scholar
  150. 150.
    Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–7.PubMedCrossRefGoogle Scholar
  151. 151.
    Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2010;6:CD000545.Google Scholar
  152. 152.
    Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;10:CD000545.PubMedGoogle Scholar
  153. 153.
    Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;10:CD000067.Google Scholar
  154. 154.
    de Boer NKH, Peyrin-Biroulet L, Jharap B, et al. Thiopurines in inflammatory bowel disease: new findings and perspectives. J Crohns Colitis. 2017. [Epub ahead of print].Google Scholar
  155. 155.
    Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Van Asseldonk DP, de Boer NK, Peters GJ, et al. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. Curr Drug Metab. 2009;10:981–97.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010;16:1541–9.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149:907–17.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–13.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Yarur AJ, Gondal B, Hirsch A, et al. Higher thioguanine nucleotide metabolite levels are associated with better long-term outcomes in patients with inflammatory bowel diseases. J Clin Gastroenterol. 2017. [Epub ahead of print].Google Scholar
  161. 161.
    Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904–15.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640–7.PubMedCrossRefGoogle Scholar
  163. 163.
    Sparrow MP. Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2008;4:505–11.Google Scholar
  164. 164.
    Nagy F, Molnar T, Szepes Z, et al. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol. 2008;14:4342–6.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Bermejo F, Lopez-Sanroman A, Algaba A, et al. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:120–4.PubMedCrossRefGoogle Scholar
  166. 166.
    Herfarth HH, Kappelman MD, Long MD, et al. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22:224–33.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The north American Crohn’s study group investigators. N Engl J Med. 1995;332:292–7.PubMedCrossRefGoogle Scholar
  168. 168.
    McDonald JW, Wang Y, Tsoulis DJ, et al. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD003459.Google Scholar
  169. 169.
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s study group investigators. N Engl J Med. 2000;342:1627–32.PubMedCrossRefGoogle Scholar
  170. 170.
    Patel V, Wang Y, MacDonald JK, et al. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD006884.Google Scholar
  171. 171.
    Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;18:57–63.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59:1363–8.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13:1118–24.PubMedCrossRefPubMedCentralGoogle Scholar
  174. 174.
    Roblin X, Boschetti G, Williet N, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017;46:142–9.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45:276–82.PubMedCrossRefGoogle Scholar
  176. 176.
    Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444–7.PubMedCrossRefGoogle Scholar
  177. 177.
    Bots S, Gecse K, Barclay M, D'Haens G. Combination Immunosuppression in IBD. Inflamm Bowel Dis. 2018;24:539–45.PubMedCrossRefGoogle Scholar
  178. 178.
    Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1293–301.PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.PubMedCrossRefGoogle Scholar
  181. 181.
    Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618–27.PubMedCrossRefGoogle Scholar
  182. 182.
    Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–41.PubMedCrossRefGoogle Scholar
  183. 183.
    Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:1709–18.PubMedCrossRefGoogle Scholar
  184. 184.
    Ben-Horin S. Drug level-based anti-tumor necrosis factor therapy: ready for prime time? Gastroenterology. 2015;148:1268–71.PubMedCrossRefGoogle Scholar
  185. 185.
    Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opin Drug Saf. 2017;16:303–17.PubMedCrossRefGoogle Scholar
  186. 186.
    Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26:1457–64.PubMedCrossRefGoogle Scholar
  187. 187.
    Shen B, Fazio VW, Remzi FH, et al. Endoscopic balloon dilation of ileal pouch strictures. Am J Gastroenterol. 2004;99:2340–7.PubMedCrossRefGoogle Scholar
  188. 188.
    Reese GE, Purkayastha S, Tilney HS, et al. Strictureplasty vs resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Color Dis. 2007;9:686–94.CrossRefGoogle Scholar
  189. 189.
    Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50:1968–86.PubMedCrossRefGoogle Scholar
  190. 190.
    Fearnhead NS, Chowdhury R, Box B, et al. Long-term follow-up of strictureplasty for Crohn’s disease. Br J Surg. 2006;93:475–82.PubMedCrossRefGoogle Scholar
  191. 191.
    Matzke GM, Kang AS, Dozois EJ, et al. Mid pouch stricturoplasty for Crohn’s disease after ileal pouch-anal anastomosis: an alternative to pouch excision. Dis Colon Rectum. 2004;47:782–6.PubMedCrossRefGoogle Scholar
  192. 192.
    Wu XR, Mukewar S, Kiran RP, et al. Surgical stricturoplasty in the treatment of ileal pouch strictures. J Gastrointest Surg. 2013;17:1452–61.PubMedCrossRefGoogle Scholar
  193. 193.
    Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn’s disease. Dis Colon Rectum. 1996;39:893–8.PubMedCrossRefGoogle Scholar
  194. 194.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.PubMedCrossRefGoogle Scholar
  195. 195.
    Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85.PubMedCrossRefGoogle Scholar
  196. 196.
    Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004;2:912–20.PubMedCrossRefGoogle Scholar
  197. 197.
    Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–8.PubMedPubMedCentralCrossRefGoogle Scholar
  198. 198.
    Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63:1381–92.PubMedCrossRefGoogle Scholar
  199. 199.
    Molendijk I, Peeters KC, Baeten CI, et al. Improving the outcome of fistulising Crohn’s disease. Best Pract Res Clin Gastroenterol. 2014;28:505–18.PubMedCrossRefGoogle Scholar
  200. 200.
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–42.PubMedCrossRefGoogle Scholar
  201. 201.
    Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and Management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135–49.PubMedCrossRefGoogle Scholar
  202. 202.
    West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329–36.PubMedCrossRefGoogle Scholar
  203. 203.
    Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Gastroenterology and Department of Clinical and Experimental MedicineLinköping UniversityLinköpingSweden

Personalised recommendations